Tirapazamine: Hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Shibata, T ^a   Shibamoto, Y ^a   Sasai, K ^a   Oya, N ^a   Murata, R ^a   Takagi, T ^a   Hiraoka, M ^a   Takahashi, M ^a   Abe, M ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Cytokinesis block micronucleus assay; Hypoxia; KU 2285; Radiation; Tirapazamine

Indexed keywords

2,2 DIFLUORO N (2 HYDROXYETHYL) 3 (2 NITRO 1 IMIDAZOLYL)PROPIONAMIDE; CYTOCHALASIN B; RADIOSENSITIZING AGENT; TIRAPAZAMINE; ANTINEOPLASTIC AGENT; NITROIMIDAZOLE DERIVATIVE; TRIAZINE DERIVATIVE;

ANIMAL CELL; CELL SUSPENSION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINESIS; DOSE RESPONSE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HYPOXIA; LOW ENERGY RADIATION; MELANOMA CELL; MICRONUCLEUS TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ARTICLE; CELL CULTURE; CELL HYPOXIA; DRUG EFFECT; MICRONUCLEUS; RADIATION RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MICE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MICRONUCLEUS TESTS; NITROIMIDAZOLES; RADIATION-SENSITIZING AGENTS; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0030013852     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. BROWN JM. (1993). SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br. J. Cancer, 67, 1163-1170.
2. BROWN JM AND GIACCIA AJ. (1994). Tumor hypoxia: the picture has changed in the 1990s. Int. J. Radiat. Biol., 65, 95-102.
3. BROWN JM AND LEMMON MJ. (1990). Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50, 7745-7749.
4. DOHERTY N, HANCOCK SL, KAYE S, COLEMAN CN, SHULMAN L, MARQUEZ C, MARISCAL C, RAMPLING R, SENAN S AND ROEMELING RV. (1994). Muscle cramping in Phase I clinical trials of Tirapazamine (SR 4233) with and without radiation. Int. J. Radiat. Oncol. Biol. Phys., 29, 379-382.
5. HILL RP. (1986). Sensitizers and radiation dose fractionation: Results and interpretations. Int. J. Radiat. Oncol. Biol. Phys., 12, 1049-1054.
6. HIRST DG, BROWN JM AND HAZLEHURST JL. (1982). Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Br. J. Cancer, 46, 109-116.
7. KIM IH AND BROWN JM. (1994). Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int. J. Radiat. Oncol. Biol. Phys., 29, 493-497.
8. LAMBIN P, GUICHARD M, CHAVAUDRA N AND MALAISE EP. (1992). The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity. Radiother. Oncol., 24, 201-204.
9. MINCHINTON AI AND BROWN JM. (1992). Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing. Br J. Cancer, 66, 1053-1058.
10. PEEBLES RT, TRISH T AND PAPAGEORGE AG. (1978). Isolation of four unusual pediatric solid tumor cell lines. Pediatr. Res., 12, 485.
11. SASAI K, NISHIMOTO S, SHIMOKAWA K, HISANAGA Y, KITAKABU Y, SHIBAMOTO Y, ZHOU L, WANG J, TAKAHASHI M, KAGIYA T AND ABE M. (1991). A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys., 20, 1249-1254.
12. SENAN S. (1995) Vasoactivity, a potentially important variable in the sequencing of tirapazamine (SR 4233) and radiation (letter). Int. J. Radiat. Oncol. Biol. Phys., 31, 209.
13. SHIBAMOTO Y, NISHIMOTO S, SHIMOKAWA K, HISANAGA Y, ZHOU L, WANG J, SASAI K, TAKAHASHI M, ABE M AND KAGIYA T. (1989). Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitisers. Int. J. Radiat. Oncol. Biol. Phys., 16, 1045-1048.
14. SHIBAMOTO Y, STREFFER C, FUHRMANN C AND BUDACH V. (1991). Tumor radiosensitivity prediction by the cytokinesis-block micronucleus assay. Radiat. Res., 128, 293-300.
15. SHIBAMOTO Y, STREFFER C, SASAI K, OYA N AND ABE M. (1992). Radiosensitization efficacy of KU-2285, RP-170, and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay. Int. J. Radiat. Biol., 61, 473-478.
16. SHIBAMOTO Y, SHIBATA T, MIYATAKE S, ODA Y, MANABE T, OHSHIO G, YAGI K, STREFFER C, TAKAHASHI M AND ABE M. (1994). Assessment of the proliferative activity and radiosensitivity of human tumors using the cytokinesis-block micronucleus assay. Br. J. Cancer, 70, 67-71.
17. SHIBATA T, SHIBAMOTO Y, OYA N, SASAI K, MURATA R, ISHIGAKI T AND ABE M. (1994). Comparison of radiosensitising effect of KU-2285 and SR-2508 at low drug concentrations and doses. Int. J. Rudiat. Oncol. Biol. Phys., 29, 587-590.
18. SHIBATA T, SHIBAMOTO Y, SASAI K. OYA N, TAKAGI T, MURATA R AND ABE M. (1995). Assessment of micronucleus induction in SCCVII cells treated with bioreductive agents. WIN 59075 (SR 4233) and mitomycin C, under aerobic and hypoxic conditions. Mutat. Res., 342, 171-177.
19. SHIBATA T, SHIBAMOTO Y, SASAI K, OYA N, MURATA R, TAKAGI T AND ABE M. (1996). Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation. Jpn. J. Cancer Res., 87 (in press).
20. STRATFORD IJ AND STEPHENS MA. (1989). The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radiat. Oncol. Biol. Phys., 16, 973-976.
21. ZEMAN EM AND BROWN JM. (1991). Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications. Int. J. Radiat. Biol., 59, 117-131.
22. ZEMAN EM, BROWN JM, LEMMON MJ, HIRST VK AND LEE WW. (1986). SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12, 1239-1242.
23. ZEMAN EM, LEMMON MJ AND BROWN JM. (1990). Aerobic radiosensitisation by SR4233 in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys., 18, 125-132.